Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Pharma giant targets new standards of care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
